Solwers posted a weak Q1, with revenue largely in line with our expectation but profitability clearl...
Redeye provides a research update following MindArk’s softer-than-expected Q1 report.
Redeye comments on the positive phase I results for IRL757 announced by IRLAB.
Redeye comments on Verve Group’s Q1 2025 results, which were in line with expectations in terms of t...
Solwers reported its results for Q1 (condensed business review) with sales of EUR 20.
Redeye comments on SynAct's Q1 report, which includes the initiation of a new phase II study in Deng...
Chordate Medical redovisade ökad nettoomsättning och minskad rörelseförlust i det första kvartalet.
Redeye comments on Klaria’s announcement earlier today regarding a SEK9.
2025 has turned out to be a very intense period so far, including a SEK 23m fundraising, publication...
Hansa Biopharma plans to restructure the organisation to optimise resource allocation and improve op...
Redeye comments on Lipigon’s first quarter report 2025.
Redeye comments on Active Biotech’s multiple myeloma results, which were in line with previous reado...
Redeye provides its preview of Integrum’s Q4 2024 report, due on Tuesday, June 3.
Redeye provides an update following Jumpgate’s Q1 2025 report, where we observed a top line largely ...
Stayble Therapeutics redovisade ingen nettoomsättning och en minskad rörelseförlust under det första...
